Prediction of response to neoadjuvant chemotherapy in breast cancer patients by circulating apoptotic biomarkers nucleosomes, DNAse, cytokeratin-18 fragments and survivin

Clinical significance of serum M30 and M65 levels in patients with breast cancer

“…Assessment of soluble CK18 fragments has been shown to facilitate discrimination between normal and cancer patients and to be of value in prognosis assessment and monitoring of response to therapy [2,3,7,14,[19][20][21][22][23]. M30 and M65 are relatively new markers that detect different circulating forms of the epithelial cell structural protein CK18.…”

“…These assays were also studied in serum or plasma of patients with breast cancer [18][19][20][21][22][23]. In literature, only a limited number of studies have investigated serum M30 and M65 levels in human breast cancer [18][19][20][21][22][23].…”

“…In literature, only a limited number of studies have investigated serum M30 and M65 levels in human breast cancer [18][19][20][21][22][23]. In pioneering study, Biven et al evaluated the relationship between serum M30 level and tumor response to chemotherapy in 32 recurrent breast cancer patients [18].…”

“…Additionally, these assays have been reported as having prognostic markers in several malignancies, such as testicular, gastric, pancreatic, colorectal, lung cancers, and others [3,[8][9][10][11][12][13][14][15][16][17]. Although these available findings existed in the other tumors, there are a few clinical studies to investigate the clinical significance of these assays in breast cancer [18][19][20][21][22][23]. The diagnostic, predictive and prognostic importance of measuring soluble products of CK18 is underlined by the previous studies demonstrating conflicting results.…”

CNAPS in Therapy Monitoring

“…Moreover, nucleosomes, progastrin-releasing peptide (ProGRP) and CYFRA 21-1 indicated therapy response after the first course of treatment in 128 patients with small cell lung cancer, too [75]. Furthermore, the capacity of nucleosomes to indicate early tumor response to therapy was demonstrated for patients with colorectal [76,77], pancreatic [78,79] and breast cancer [80] undergoing systemic chemo-and radiotherapy as well as for patients with primary and secondary liver cancer receiving local chemo-and radiotherapies such as transarterial chemoembolization (TACE) and selective internal radiotherapy (SIRT) [81,82]. According to these approaches, the blood collection before every treatment cycle and during the first therapy week, as well as the consideration of a strictly standardized pre-analytical collection protocol, were very important in obtaining reliable data.…”